



# 12<sup>th</sup> European Congress of Neuropathology

**NOW VIRTUAL** • 31 May - 3 June 2021 

# PROGRAM

Denmark, 2021



Scandinavian  
Neuropathological  
Society

# Content

ECNP2021

---

Congress Welcome .....	3
Welcome from the President of Euro-CNS .....	4
Organising Committee.....	5
Scientific Program Committee and Advisory Board .....	6
Practical information .....	7
Program at-a-glance .....	8
ECNP 2021 Program.....	12
Monday .....	12
Tuesday .....	17
Wednesday .....	21
Thursday .....	25
Free Communication sessions.....	29
Quick Pitch Sessions .....	32
Supporters and Partner/Sister Organizations .....	42
Exhibitors.....	43
Acknowledgements.....	44

# Welcome from the Congress President and the Scandinavian Neuropathological Society (SNS)

ECNP2021

## Dear Friends and Colleagues,

On behalf of the Organizing and Scientific Program Committees, it is a great pleasure for me to welcome you to the 12<sup>th</sup> European Congress of Neuropathology. The Scandinavian Neuropathological Society has considered it a great honor to organize this Congress together with Euro-CNS.

Originally, the 12<sup>th</sup> European Congress of Neuropathology was going to take place in June 2020 in Odense, the warm fairytale city in the heart of Denmark. However, the COVID-19 pandemic led to a complete national lock-down in Denmark less than 3 months before the congress last year.

After postponing the congress to October 2020, the continued COVID-19 pandemic led us to decide to switch to a virtual event – the first virtual European Congress of Neuropathology– to bring neuropathology into this novel virtual age and to share the important knowledge in our field.

Neuropathology is an important discipline. The diseases we cover are critical for our patients and their relatives and our focus on novel diagnostic approaches including molecular mechanisms explaining pathological and clinical manifestations of neurological diseases is highly needed.

Together with our Scientific Program Committee with both Scandinavians and experts from all over Europe and representing all the different areas of expertise in neuropathology, we have the pleasure to present a very diverse program.

While our program is research driven with 6 plenary lectures and 13 symposia intended to inform the delegates about the most recent developments, research and results, the 9 workshops will illustrate the more practical approach of how new knowledge is integrated into daily neuropathology. Importantly and being of high relevance, we have a symposium on the neuropathological aspects of COVID-19.

The purpose of the Free Communications and Poster Quick Pitches is to integrate more deeply into the congress all the important knowledge of the 245 abstracts submitted for the congress.



**Bjarne Winther Kristensen**  
Congress President

The eposter platform, the Learning Toolbox, connects the delegates with the poster presenters in a unique way. Questions can be asked realtime via chat - so poster presenters will be easy to reach and leave the meeting with new connections, knowing that many have seen their presentations.

I deeply appreciate all the help and support from the Organizing and Scientific Committees, from Euro-CNS and SNS and many other sides to organize the 12<sup>th</sup> European Congress of neuropathology. We are extremely grateful for support from both our scientific and industry sponsors.

Hereby a warm welcome to the 12<sup>th</sup> European Congress of Neuropathology – we hope you will enjoy the congress and that it will lead to new collaborations and future discoveries.

On behalf of the Organizing and Scientific Program Committee,

A handwritten signature in blue ink that reads "Bjarne Winther Kristensen".

**Bjarne Winther Kristensen**

Congress President

Chairman of the Organizing and Scientific Committees  
President, Scandinavian Neuropathological Society (SNS)

# Welcome from the President of Euro-CNS

ECNP2021


## Dear Friends and Colleagues,

It gives me great pleasure to welcome the neuropathological community to this 12<sup>th</sup> European Congress of Neuropathology. As most of you will know, this Congress was originally planned for June 2020 in the City of Odense, Denmark. A beautiful congress setting was arranged to host an exciting scientific program in combination with a marvellous social program. COVID-19 decided otherwise. At first, the program was postponed to October 2021, in the hope a live Congress would be possible at that time. Finally, it was decided to organise a virtual Congress from the 31<sup>st</sup> of May to the 3<sup>rd</sup> of June 2021.

And here we are. The local organizing committee of the Scandinavian Neuropathological Society, led by the incredible Prof. Bjarne Winter Kristensen, persevered and will now offer you a thrilling event with an impressive scientific content, including the classic neuropathological themes of neurodegeneration, brain tumours, epilepsy, neurodevelopment, muscle and nerve pathology and other themes. The program also encompasses brand new themes such as neuropathology of COVID-19. These themes will be presented in plenary lectures, symposia, workshops, free communication sessions and poster sessions.

But now, it is your turn, dear colleagues. The organizing committee did its utmost best to enable interaction between the speakers, abstract presenters and delegates. Although several of the presentations will be recorded before the congress, most presentations, the moderation and the discussions will be live. You will be invited to ask questions and interact so that we can keep the delegates optimally engaged. There will be opportunity for this during the symposia, the workshops, the free communication sessions and the poster Quick Pitch sessions. The main virtual lecture halls will be named after fairy tales of Hans Christian Andersen, who was born in the city of Odense and lived there for a long time. Perhaps this will inspire you to read Andersen's beautiful stories again and pick up a scent of the Danish culture.

I am extremely grateful to the Organizing Committee, especially to Prof. Bjarne Winter Kristensen; to the Scientific Committee; to the Odense University Hospital for financial backup; to the sponsors and exhibitors of the event and to all the people who helped in any way with all the practical work. And last but not least, I am very grateful to you for your active participation in this Congress.



### **Martin Lammens**

President, European Confederation of Neuropathological Societies (Euro-CNS)



# Committees

ECNP2021

## Organizing committee:

**Prof. Bjarne Winther Kristensen (chair)**

Rigshospitalet, Copenhagen University Hospital,  
University of Copenhagen, Copenhagen, Denmark

**Dr. David Scheie**

Rigshospitalet, Copenhagen University Hospital,  
University of Copenhagen, Copenhagen, Denmark

**Dr. Martin Lammens**

Antwerp University Hospital, University of Antwerp,  
Antwerp, Belgium and University of Ghent, Ghent,  
Belgium

**Dr. Wilfred den Dunen**

University Medical Center Groningen, University of  
Groningen, Groningen, The Netherlands

**Prof. Henrik Daa Schrøder**

Odense University Hospital, University of Southern  
Denmark, Odense, Denmark

**Dr. Henning Boldt**

Odense University Hospital, University of Southern  
Denmark, Odense, Denmark

**Dr. Martin Wirefeldt Nielsen**

Odense University Hospital, University of Southern  
Denmark, Odense, Denmark

**Dr. Eva Løbner Lund**

Rigshospitalet, Copenhagen University Hospital,  
University of Copenhagen, Copenhagen, Denmark

**Dr. Helle Broholm**

Copenhagen University Hospital, Denmark

**Prof. Bente Finsen**

University of Southern Denmark, Odense, Denmark

**Dr. Morten Meyer**

University of Southern Denmark, Odense, Denmark

**Dr. Benedicte Parm Uihøi**

Aarhus University Hospital, Aarhus, Denmark

**Dr. Marianne Schmidt Ettrup**

Aalborg University Hospital, Aalborg, Denmark

**Dr. Jeanette Krogh Petersen**

Odense University Hospital, University of Southern  
Denmark, Odense, Denmark

**Dr. Arnon Møldrup Knudsen**

Odense University Hospital, University of Southern  
Denmark, Odense, Denmark

**Dr. Atul Anand**

Odense University Hospital, University of Southern  
Denmark, Odense, Denmark

# Committees

ECNP2021

## Scientific Program Committee and Advisory Board:

**Bjarne Winther Kristensen**

(chair, Copenhagen, Denmark)

**Pieter Wesseling**

(co-chair, Amsterdam, the Netherlands)

**Irina Alafuzoff**

(co-chair, Uppsala, Sweden)

**Steve Wharton**

(co-chair, Sheffield, United Kingdom)

**Colin Smith**

(co-chair, Edinburgh, Scotland)

**Raj Kalaria**

(co-chair, Newcastle, United Kingdom)

**Kate Lambertsen**

(co-chair, Odense, Denmark)

**Anders Oldfors**

(co-chair, Gothenburg, Sweden)

**Martin Lammens**

(co-chair, Antwerp, Belgium)

**Karen Bonde Larsen**

(co-chair, Copenhagen, Denmark)

**Eleonora Aronica**

(co-chair, Amsterdam, the Netherlands)

**Hans Lassmann**

(co-chair, Vienna, Austria)

**Trevor Owens**

(co-chair, Odense, Denmark)

**Johannes Hainfellner**

(Editor: Clinical Neuropathology)

**Alia Shamikh**

(Stockholm, Sweden)

**Anders Paetau**

(Helsinki, Finland)

**Andreas von Deimling**

(Heidelberg, Germany)

**Christine Haberler**

(Vienna, Austria)

**David Capper**

(Berlin, Germany)

**David Scheie**

(Copenhagen, Denmark)

**Dominique Figarella-Branger**

(Marseille, France)

**Elisabeth Englund**

(Lund, Sweden)

**Ellen Gelpi**

(Vienna, Austria)

**Ellen-Ann Antal**

(Oslo, Norway)

**Eva Løbner Lund**

(Copenhagen, Denmark)

**Felice Giangaspero**

(Roma, Italy)

**Felix Sahn**

(Heidelberg, Germany)

**Gabor Kovacs**

(Toronto, Canada)

**Guido Reifenberger**

(Düsseldorf, Germany)

**Helle Broholm**

(Copenhagen, Denmark)

**Henrik Daa Schrøder**

(Odense, Denmark)

**Homa Adle-Biassette**

(Paris, France)

**Hrvoje Miletic**

(Bergen, Norway)

**Ida Elisabeth Holm**

(Aarhus, Denmark)

**Inger Nennesmo**

(Stockholm, Sweden)

**James Nicoll**

(Southampton, United Kingdom)

**Jens Pahnke**

(Oslo, Norway)

**Joachim Weis**

(Aachen, Germany)

**Maria Gardberg**

(Turku, Finland)

**Maria Thom**

(London, United Kingdom)

**Martin Wirenfeldt Nielsen**

(Odense, Denmark)

**Miguel Idoate**

(Navarra, Pamplona, Spain)

**Olivera Casar-Borota**

(Uppsala, Sweden)

**Olli Tynninen**

(Helsinki, Finland)

**Pascale Varlet**

(Paris, France)

**Paul G Ince**

(Sheffield, United Kingdom)

**Rahul Phadke**

(London, United Kingdom)

**Sanna Huovinen**

(Helsinki, Finland)

**Sverre Helge Torp**

(Trondheim, Norway)

**Sverre Mørk**

(Bergen, Norway)

**Thomas Brännström**

(Umeå, Sweden)

**Tom Jacques**

(London, United Kingdom)

**Tuomas Rauramaa**

(Kuopio, Finland)

**Werner Stenzel**

(Berlin, Germany)

# Practical information

ECNP2021

## Congress webpage

[www.ecnp2021.dk](http://www.ecnp2021.dk)

## Virtual Meeting Platform

<https://crowdcomms.com/ecnp12>

Only registered participants can access the virtual platform and access the program. Just click the link in the agenda in the menu, or in the live stream icon in the reception area, to attend a live session.

## On-demand viewing

All sessions except the Quick Pitch sessions will be recorded and available for on-demand viewing within 24 hours following the end of the session.

## Accessibility

Registered delegates can access the event platform until 1 September 2021.

## Registration

Registration is open until 15 August 2021.

## CME certificate (max. 16 credits)

To obtain your certificate (max 16 credits), please do the following:

- A) Complete the online evaluation event form that you can access via the platform main menu or via the delegate bag in the reception area.
- B) Once you have attended all sessions you would like to receive the CME credits for, please request the CME certificate via the **request form** on the virtual platform or in the Euro-CNS virtual booth in the Exhibit area.

You will then receive your certificate from the Euro-CNS/ECNP office within four weeks following completion of your form.

## FAQ (Frequently Asked Questions)

We highly recommend reading the section with FAQ on the event platform.

## Event support

### Euro-CNS/ECNP office

-For speakers and presenters

[secretariat@euro-cns.com](mailto:secretariat@euro-cns.com)

-For ePoster questions from 30 May-3 June

[info@kubify.co](mailto:info@kubify.co)

[support@euro-cns.com](mailto:support@euro-cns.com)

-For registration matters

[ecnp2021@euro-cns.com](mailto:ecnp2021@euro-cns.com)

### First Sight Media

Technical support is available until 3 June

First Sight Media: [ecnp@firstsight.media](mailto:ecnp@firstsight.media)

## Contact information of the co-organizing societies

### Scandinavian Neuropathological Society (SNS)

website: <http://s-n-s.org/>

Contact: [david.scheie@regionh.dk](mailto:david.scheie@regionh.dk)

### European Confederation of Neuropathological Societies (Euro-CNS)

Website: [www.euro-cns.org](http://www.euro-cns.org)

Secretariat: [secretariat@euro-cns.com](mailto:secretariat@euro-cns.com)

## Social media:



[company/euro-cns](#)



Congress of  
Neuropathology  
2021



[ECNP2021](#)

# Program at-a-glance

ECNP2021

Monday, 31 May

CEST	PROGRAM STRUCTURE VIRTUAL ECNP - 3 CHANNEL STREAMING		
<b>12:00</b>	Exhibit / Poster Viewing / Quick Pitches		
12:15			
12:30			
12:45			
13:00			
<b>13:00</b>	Welcome		
13:15	<b>Plenary lecture 1; Andreas von Deimling, Germany</b> Brain tumor diagnosis in transition - from single parameter analyses to multiomics		
<b>13:15</b>			
13:30			
13:45			
14:00			
<b>14:00</b>	<b>Symposium 1</b> Cerebrovascular diseases	<b>Symposium 2</b> Genetics of neurodegeneration	<b>Symposium 3</b> CNS tumor precision oncology - what is important in the neuropathological setting?
14:15			
14:30			
14:45			
15:00			
15:15	Break		
15:30			
<b>15:30</b>	<b>Workshop 1</b> Primary tauopathies	<b>Workshop 2</b> Muscle biopsy and molecular biology; a successful cooperation	<b>Workshop 3</b> Pituitary and sellar lesions
15:45			
<b>15:45</b>			
16:00			
16:15			
16:30	Break		
16:45			
17:00			
17:15			
<b>17:15</b>	Break		
17:30			
<b>17:30</b>	<b>Plenary lecture 2; Dennis W Dickson, USA</b> Lessons Learned from brain banking for neurodegenerative diseases (Lecture supported by BNS and NAN)		
17:45			
18:00			
18:15			



# Program at-a-glance

ECNP2021

Tuesday, 1 June

CEST	PROGRAM STRUCTURE VIRTUAL ECNP - 3 CHANNEL STREAMING		
<b>12:00</b>	Exhibit / Poster Viewing / Quick Pitches		
12:15			
12:30			
12:45			
13:00			
<b>13:00</b>			
13:15			
13:30			
13:45			
<b>13:45</b>	Break		
14:00	Break		
<b>14:00</b>	<b>Symposium 4</b>	<b>Symposium 5</b>	<b>Symposium 6</b>
14:15	The 2021 WHO CNS tumor classification: The Fifth! (Symposium supported by BNS and NAN)	Mechanisms of brain inflammation	Immuno-oncology
14:30			
14:45			
15:00			
15:15			
15:30			
<b>15:30</b>	Break		
15:45	Break		
<b>15:45</b>	<b>Workshop 4</b>	<b>Workshop 5</b>	<b>Workshop 6</b>
16:00	Slide seminar on human prion diseases - histotyping and identification of atypical phenotypes	Case discussions of CNS tumors with multilayered information	Developmental neuropathology; recent advances and future challenges
16:15			
16:30			
16:45			
17:00			
17:15			
<b>17:15</b>	Break		
17:30	Break		
<b>17:30</b>	<b>Free Communication 1</b>	<b>Free Communication 2</b>	<b>Free Communication 3</b>
17:45	Free Communication 1	Free Communication 2	Free Communication 3
18:00			
18:15			
18:30			

# Program at-a-glance

ECNP2021

Wednesday, 2 June

CEST	PROGRAM STRUCTURE VIRTUAL ECNP - 3 CHANNEL STREAMING		
<b>12:00</b>	Exhibit / Poster Viewing / Quick Pitches		
12:15			
12:30			
12:45			
13:00			
<b>13:00</b>			
13:15			
13:30			
13:45			
<b>13:45</b>	Break		
14:00	Break		
<b>14:00</b>	<b>Symposium 7</b>	<b>Symposium 8</b>	<b>Symposium 9</b>
14:15	TDP-43 proteinopathies	Myositis - clinical, morphological and differential diagnostic highlights	White matter and oligodendrocyte pathology; new insights in neurodevelopmental diseases and epilepsy
14:30			
14:45			
15:00			
15:15			
15:30	Break		
<b>15:30</b>	Break		
15:45	Break		
<b>15:45</b>	<b>Workshop 7</b>	<b>Workshop 8</b>	<b>Workshop 9</b>
16:00	Assessment of the contributions of mixed pathologies in the ageing brain	Progress in the pathological diagnosis of pediatric and adult CNS tumors	B-cells in inflammatory demyelinating diseases
16:15			
16:30			
16:45			
17:00			
17:15	Break		
<b>17:15</b>	Break		
17:30	Break		
<b>17:30</b>	<b>Free Communication 4</b>	<b>Free Communication 5</b>	<b>Free Communication 6</b>
17:45	Free Communication 4	Free Communication 5	Free Communication 6
18:00			
18:15			
18:30			

# Program at-a-glance

ECNP2021

Thursday, 3 June

CEST	PROGRAM STRUCTURE VIRTUAL ECNP - 3 CHANNEL STREAMING						
<b>11:30</b>	<b>ISN business meeting*</b> * ISN Council & Executive only (upon invitation)						
11:45							
<b>12:00</b>				<b>Exhibit / Poster Viewing / Quick Pitches</b>			
12:15							
12:30							
12:45							
13:00	<b>Plenary lecture 5; Berge Minassian, USA</b>  Polyglucosan storage in muscle and brain - disease entities and pathogenesis						
<b>13:00</b>							
13:15							
13:30							
13:45	<b>Break</b>						
<b>14:00</b>	<b>Symposium 10</b> Neuropathology training, courses and examination (EFN) in Europe						
14:15				<b>Symposium 11</b> Intratumoral heterogeneity			
<b>14:00</b>						<b>Symposium 12</b> Dynamic aspects of amyloid- $\beta$	
14:15							
14:30							
14:45							
15:00							
15:15	<b>Break</b>						
<b>15:30</b>	<b>Symposium 13</b> COVID-19 and neuropathology						
15:45							
<b>15:45</b>							
16:00							
16:15							
16:30	<b>Break</b>						
16:45	<b>Plenary lecture 6; Piero Parchi, Italy</b>  Deciphering phenotypic variability and transmission properties of human prion diseases						
17:00							
17:15							
<b>17:15</b>							
17:30	<b>Break</b>						
<b>17:30</b>	<b>Prizes and closure</b>						
17:45							
18:00							
18:15							
<b>18:15</b>	<b>Prizes and closure</b>						
18:30	<b>Prizes and closure</b>						

# Plenary Speakers

ECNP2021



**Andreas von Deimling**

## Andreas von Deimling

Andreas von Deimling, received his basic medical education in the city of Freiburg, Germany.

Clinical training began with a first residency at the University Hospital Zurich, Switzerland, in 1988 followed by a research program in the Neuro-Oncology Department of the Massachusetts General Hospital from 1990 to 1992.

Neuropathology training was completed in the Department of Neuropathology at the University of Bonn from 1992 to 1994.

From 1995 to 1988 he served there as consultant and was awarded the "Schäfersnolte Award" and the endowed "Schilling Professorship".

In 1998, he was appointed as Director of Neuropathology at the Charité, Humboldt University, in the city of Berlin.

This was followed by relocation to the city of Heidelberg in 2007, accompanied by a combined appointment as director of Neuropathology at the University of Heidelberg and director of the Clinical Cooperation Unit Neuropathology at the German Cancer Institute.

His scientific focus is on molecular tumor neuropathology with special attention to developing diagnostic tools and algorithms. This included the mutation specific antibodies H09 targeting the IDH1-R132H and VE1 targeting the BRAF-V600E mutations. Recent work focused on a methylation based classification systems for brain tumors and sarcomas.

He is a member of the European Academy of Cancer Sciences and the German National Academy of Sciences (Leopoldina) and was awarded the "Deutsche Krebspreis" in 2016 and the Fred W. Stewart award in 2017.

# Plenary Speakers

ECNP2021

## Dennis Dickson

Dennis W. Dickson is a 1982 graduate of the University of Iowa College of Medicine.

He completed Pathology and Neuropathology training at Albert Einstein College of Medicine in New York City in 1986 and was a faculty member at Einstein until 1997.

He moved to Mayo Clinic in Florida in 1997, where he established a brain bank for neurodegenerative disorders with a focus on Alzheimer's disease (AD), Lewy body dementia (LBD) and progressive supranuclear palsy (PSP).

The brain bank houses the world's largest collections of pathologically-confirmed cases of PSP and corticobasal degeneration (CBD), as well as very large collections of AD and LBD cases, all of which have been used in multicenter, international studies to understand the genetic architecture of neurodegenerative disorders.

His contributions have been recognized by the Metropolitan Life Award in 2001, the Fred Springer Award from the American Parkinson Disease Association in 2008, the Alfred Meyer Award from the British Neuropathological Society in 2009, the Potamkin Prize in 2011 and the Award for Meritorious Contributions to Neuropathology from the American Association of Neuropathologists in 2016.

He is past president of the American Association of Neuropathologists and editor of a monograph sponsored by the International Society of Neuropathology, now in its second edition, entitled "Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders."



**Dennis Dickson**

# Detailed Program

ECNP2021

Monday, 31 May 2021

Times are in Central European Summer Time (CEST, Copenhagen)

**09:00-18:30 - Exhibit Hall and ePoster viewing open**

**12:00-13:00 - Quick Pitch poster sessions** (mini oral poster presentations). See presentation overview below

- 12:00 Quick Pitch session 1: Gliomas
- Quick Pitch session 2: Tumors
- Quick Pitch session 3: Neurodegenerative diseases
- Quick Pitch session 4: Neuroinflammatory diseases

**13:00 -13:15 - Welcome** (Nightingale Auditorium)

- 13:00 Bjarne Winther Kristensen, Congress President and President of SNS, Copenhagen, Denmark
- Martin Lammens, President of Euro-CNS, Antwerpen, Belgium

**13:15-14:00 - Plenary Lecture 1** (Nightingale Auditorium)

- 13:15 **Chair:** Bjarne Winther Kristensen, Copenhagen, Denmark
- Brain tumor diagnosis in transition - from single parameter analyses to multiomics**
- Andreas von Deimling, Heidelberg, Germany

**14:00-15:30 - Symposium 1: Cerebrovascular diseases** (Nightingale Auditorium)

- Chairs:** Raj Kalara, Newcastle, United Kingdom, and Kate Lykke Lambertsen, Odense, Denmark
- 14:05 **S1.1 Post-stroke inflammation – target or tool for therapy**  
Kate Lykke Lambertsen, Odense, Denmark
- 14:28 **S1.2 White matter in familial small vessel diseases: CADASIL**  
Anne Joutel, Paris, France
- 14:51 **S1.3 White matter disease – small vessel pathology and more**  
Elisabet Englund, Lund, Sweden
- 15:13 **S1.4 (P207) Regional proteomic mapping of the human vanishing white matter brain**  
Jodie Man, Utrecht, the Netherlands
- 15:22 **S1.5 (P210) Volume and cell number of the hippocampus in depression, schizophrenia, and suicide subjects**  
Karl-Anton Dorph-Petersen, Århus/ Randers, Denmark

**14:00-15:30 - Symposium 2: Genetics of neurodegeneration** (Tinderbox Hall)

- Chairs:** Irina Alafuzoff, Uppsala, Sweden, and Colin Smith, Edinburgh, Scotland
- 14:05 **S2.1 Clues to the aetiology of neurodegenerative diseases from genomic analysis**  
John Hardy, London, United Kingdom
- 14:28 **S2.2 Pathology of genetic and sporadic Parkinson's disease**  
Steve Gentleman, London, United Kingdom
- 14:51 **S2.3 Genetics of ALS/MND - from genes to translational approaches**  
Pamela Shaw, Sheffield, United Kingdom
- 15:14 **Panel Discussion**

# Detailed Program

ECNP2021

Monday, 31 May 2021

## 14:00-15:30 - Symposium 3. CNS tumor precision oncology – what is important in the neuropathological setting? (Little Mermaid Hall)

**Chairs:** Werner Paulus, Münster, Germany, and Christine Haberler, Vienna, Austria

14:05 **S3.1 The laboratory setup needed for CNS tumor precision oncology**

Felix Sahm, Heidelberg, Germany

14:25 **S3.2. Experience and results from a precision oncology phase I unit**

Ulrik Lassen, Copenhagen, Denmark

14:45 **S3.3 Molecular diagnostics of brain tumors - current practice and the next frontiers**

Sebastian Brandner, London, United Kingdom

15:05 **S3.4 (P192) Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma**

Christian Mirian, Copenhagen/Geneva, Denmark/Switzerland

15:13 **S3.5 (P123) Diffuse midline glioma, H3 K27M-mutant (DMG,H3) with BRAF V600E mutation Presentation of two cases treated with BRAF V600 inhibitors**

Mónica Mezmezian, Buenos Aires, Argentina

15:30-15:45 - Break. Please visit the Exhibition Hall and ePosters

## 15:45-17:15 - Workshop 1. Primary tauopathies (Nightingale Auditorium)

**Chairs:** Gabor Kovacs, Toronto, Canada, and Dennis Dickson, Jacksonville, Florida, USA

15:50 **W1.1 Overview of tau pathologies: interactive slide session using scanned slides**

Gabor Kovacs, Toronto, Canada

16:15 **W1.2 Tau pathology related to brain trauma**

Colin Smith, Edinburgh, Scotland

16:40 **W1.3 (P023) Deconvolving the individual contributions of comorbid tau neuropathologies using deep learning**

Anthony Vega, Dallas, Texas, USA

16:48 **W1.4 (P019) Aggregates of RNA binding proteins and ER chaperones linked to exosomes in granulovacuolar degeneration of the Alzheimer's disease brain**

Alfred Yamoah, Aachen, Germany

16:56 **W1.5 (P018) Tau related changes in post mortem retina in Alzheimer's disease and other tauopathies**

Jeroen Hoozemans, Amsterdam, the Netherlands

17:04 **Panel Discussion**

# Detailed Program

ECNP2021

Monday, 31 May 2021

## 15:45-17:15 - Workshop 2. Muscle biopsy and molecular biology: a successful cooperation (Tinderbox Hall)

**Chairs:** Martin Lammens, Antwerpen, Belgium, and Werner Stenzel, Berlin, Germany

15:49 **W2.1 Interactive case discussions**

Eleonora Aronica, Amsterdam, the Netherlands

16:02 **W2.2 Interactive case discussions**

Joachim Weis, Aachen, Germany

16:15 **W2.3 Differential diagnosis of vacuolar myopathies in the NGS era**

Joachim Weis, Aachen, Germany

16:26 **W2.4 Interactive case discussions**

Willem de Ridder, Antwerp, Belgium

16:41 **W2.5 Interactive case discussions**

Wilfred den Dunnen, Groningen, the Netherlands

16:54 **W2.6 Interactive case discussions**

Werner Stenzel, Berlin, Germany

17:07 **W2.7 (P206) Automated large-scale scanning transmission electron microscopy of myopathies with structural abnormalities**

Carsten Dittmayer, Berlin, Germany

## 15:45-17:15 - Workshop 3. Pituitary and sellar lesions (Little Mermaid Hall)

**Chairs:** Olivera Casar-Borota, Uppsala, Sweden, and Henning Boldt, Odense, Denmark

15:50 **W3.1 The 2017 WHO classification of pituitary neuroendocrine neoplasms. What have we learnt?**

Olivera Casar-Borota, Uppsala, Sweden

16:07 **W3.2 Morphology meets genomics and epigenomics: should we move towards an integrated tissue diagnosis of PitNETs?**

Olaf Ansorge, Oxford, United Kingdom

16:24 **W3.3 Molecular pathways and targets in pituitary tumors**

Marily Theodoropoulou, Munich, Germany

16:41 **W3.4 Pituitary lesions from an endocrinologist's perspective**

Marianne Andersen, Odense, Denmark

16:58 **W3.5 Interactive slide-based case presentations**

Olaf Ansorge, Oxford, United Kingdom

**17:15-17:30 - Break. Please visit the Exhibition Hall and ePosters**

## 17:30-18:15 - Plenary Lecture 2 (Nightingale Auditorium)

**Chair:** Colin Smith, Edinburgh, Scotland

**Lessons learned from brain banking for neurodegenerative diseases**

Dennis Dickson, Jacksonville, Florida, USA

*This Lecture is supported by the British Neuropathological Society (BNS) and Neuropathology and Applied Neurobiology (NAN)*



# Plenary Speakers

ECNP2021



**Stephanie Baulac**

## Stephanie Baulac

Stéphanie Baulac is research director at Inserm and group leader at the Paris Brain Institute (ICM, Pitié-Salpêtrière Hospital, Paris).

The scientific course of Stéphanie started as a graduate student at the Pitié-Salpêtrière in neurogenetics (Paris University, 1998-2001), her main discovery was the identification of two epilepsy genes, SCN1A and GABRG2, with major clinical impact for genetic diagnosis.

She was then a postdoctoral fellow at Harvard Medical School to investigate molecular and cellular mechanisms involved in familial forms of Alzheimer's and Parkinson's diseases.

Back in France, she has pursued her work on familial focal epilepsies, with the goal to also develop disease models and to understand the underlying mechanisms. Her team contributed to the identification of a novel gene, DEPDC5, a repressor of the mTORC1 signaling pathway, opening novel perspectives in the epilepsy field.

Currently, her main research interests are at elucidating the role of brain somatic mutations in focal cortical malformations. Towards this goal, her lab employs a multidisciplinary approach to investigate the contributions of brain mosaicism to epilepsy, integrating genetic studies, neuropathology, single-cell transcriptomics, cortical organoids and genetic mouse models.

The Baulac lab has made very important contributions to the field, and key publications have illuminated new directions in the field of genetics of epilepsy.

She has been awarded the 2019 International Michael Prize in epileptology and is funded by an ERC consolidator grant.

# Detailed Program

ECNP2021

Tuesday, 1 June 2021

**09:00-18:30 - Exhibit Hall and ePoster viewing open**

**12:00-13:00 - Quick Pitch poster sessions** (mini oral poster presentations). See presentation overview below

- 12:00 Quick Pitch session 5: Gliomas
- Quick Pitch session 6: Tumors I
- Quick Pitch session 7: Tumors II
- Quick Pitch session 8: Neuromuscular and storage disorders
- Quick Pitch session 9: Other topics

**13:00-13:45 - Plenary Lecture 3** (Nightingale Auditorium)

**Chair:** Eleonora Aronica, Amsterdam, the Netherlands  
**Brain somatic mutations in focal cortical dysplasias**  
Stéphanie Baulac, Paris, France

**13:45-14:00 - Break. Please visit the Exhibition Hall and ePosters**

**14:00-15:30 - Symposium 4. The 2021 WHO CNS tumor classification: The Fifth!** (Nightingale Auditorium)

- Chairs:** Pieter Wesseling, Amsterdam/Utrecht, the Netherlands, and Guido Reifenberger, Düsseldorf, Germany
- 14:05 **S4.1 From cIMPACT-NOW to WHO 2021 classification of CNS tumors**  
Pieter Wesseling, Amsterdam/Utrecht, the Netherlands
  - 14:25 **S4.2 The WHO 2021 classification of diffuse gliomas (adult & pediatric)**  
Guido Reifenberger, Düsseldorf, Germany
  - 14:45 **S4.3 The WHO 2021 classification of circumscribed gliomas and glioneuronal tumors**  
Dominique Figarella-Branger, Marseille, France
  - 15:05 **S4.4 Panel Discussion**
- This Symposium is supported by the British Neuropathological Society (BNS) and Neuropathology and Applied Neurobiology (NAN)*

**14:00-15:30 - Symposium 5. Mechanisms of brain inflammation** (Tinderbox Hall)

- Chairs:** Hans Lassmann, Vienna, Austria, and Trevor Owens, Odense, Denmark
- 14:05 **S5.1 Pathways of drainage of interstitial and cerebrospinal fluids from the brain. Significance for neurological diseases**  
Roxana Carare, Southampton, United Kingdom
  - 14:28 **S5.2 Immune cell interaction with the blood-brain barrier in the pathogenesis of inflammation**  
Britta Engelhardt, Bern, Switzerland
  - 14:51 **S5.3 Pathology of different human inflammatory CNS diseases - an expanding spectrum**  
Hans Lassmann, Vienna, Austria
  - 15:14 **S5.4 Panel discussion**

# Detailed Program

ECNP2021

Tuesday, 1 June 2021

## 14:00-15:30 - Symposium 6. Immuno-oncology (Little Mermaid Hall)

- 14:00 **Chairs:** Anna Berghof, Vienna, Austria, and Bjarne Winther Kristensen, Copenhagen, Denmark
- 14:05 **S6.1 The inflammatory microenvironment as a therapeutic target in glioma**  
Anna Berghof, Vienna, Austria
- 14:25 **S6.2 Genetic changes and T-cell infiltration in gliomas**  
Pim French, Amsterdam, the Netherlands
- 14:45 **S6.3 Understanding and targeting the microenvironment in IDH-mutant gliomas**  
Lukas Bunse, Mannheim, Germany
- 15:05 **S6.4 (P111) Single-cell analysis of tumor-associated microglia and macrophages from human glioblastoma**  
Rikke Sick Andersen, Odense, Denmark
- 15:13 **S6.5 (P115) Deconvolution of immunotherapy-treated glioblastoma identifies cellular heterogeneity and plasticity at the single-cell level**  
Josephine Deleuran Hendriksen, Copenhagen, Denmark
- 15:21 **S6.6 (P135) Defects of mismatch repair proteins in pediatric high-grade gliomas**  
Christine Haberler, Vienna, Austria

## 15:30-15:45 - NanoString Lecture 1 (Nightingale Auditorium)

- 15:30 **Regional and sub-regional neuroinflammatory differences in the brain of sporadic Creutzfeldt-Jakob disease patients**  
Aušrinė Areškevičiūtė, Copenhagen, Denmark

## 15:30-15:45 - Break. Please visit the Exhibition Hall and ePosters

## 15:45-17:15 - Workshop 4. Slide seminar on human prion diseases: histotyping and identification of atypical phenotypes (Nightingale Auditorium)

- 15:45 **Chairs, speakers:** Ellen Gelpi, Vienna, Austria, and Piero Parchi, Bologna, Italy
- 15:50 **W4.1 Interactive histotyping of CJD subtypes including genetic and atypical forms**

## 15:45-17:15 - Workshop 5. Case discussions of CNS tumors with multi-layered information (Tinderbox Hall)

- 15:45 **Chairs:** Felix Sahm, Heidelberg, Germany, and David Capper, Berlin, Germany
- 15:50 **W5.1. Practical NGS evaluation**  
Felix Sahm, Heidelberg, Germany
- 16:18 **W5.2. Practical DNA methylation evaluation**  
David Capper, Berlin, Germany
- 16:46 **W5.3. Interactive case discussions**  
Felix Sahm and David Capper

# Detailed Program

ECNP2021

Tuesday, 1 June 2021

**15:45-17:15 - Workshop 6. Developmental neuropathology: recent advances and future challenges**  
(Little Mermaid Hall)

- 15:45 **Chairs:** Eleonora Aronica, Amsterdam, the Netherlands, and Karen Bonde Larsen, Copenhagen, Denmark
- 15:50 **W6.1 The value of postmortem examination in neurodevelopmental diseases**  
Homa Adle-Biassette, Paris, France
- 16:10 **W6.2. Interneurons in cerebral cortical developmental disorders**  
Jeffrey Golden, Boston, USA
- 16:30 **W6.3 Neuropathology of focal cortical dysplasias: 2021 update**  
Ingmar Blümcke, Erlangen, Germany
- 16:50 **W6.4 Panel Discussion**

**17:15-17:30 - Break. Please visit the Exhibition Hall and ePosters**

**17:30-18:30 Free Communications 1-2-3.** See presentation overview below

- Free Communication Session 1: CNS Tumors (1 of 2) – Nightingale Auditorium  
Free Communication Session 2: Neurodegenerative and prion diseases (1 of 2) – Tinderbox Hall  
Free Communication Session 3: Other topics (1 of 2) – Little Mermaid Hall

# Plenary Speakers

ECNP2021

## Rolf Bjerkvig

Dr. Bjerkvig is Professor in Cell Biology, Department of Biomedicine at the University of Bergen, Norway.

Bjerkvig has served as director of the Department of Biomedicine, University of Bergen, Norway as well as Director of the Oncology Department, Luxembourg Institute of Health.

His main interests are to elucidate the mechanisms that cause tumor cell invasion and metastasis from primary and secondary brain tumors. This involves work focusing on mechanisms related to tumor/host cell interactions, -and how cells adapt within this microenvironment in order to facilitate tumor growth.

His research has also focused on mechanisms of cancer initiation and progression, with particular emphasis on cancer-initiating cells and angiogenesis and how new knowledge generated can be exploited in a therapeutic context.

For this purpose, his group has been highly recognized for the development of new model systems that reflect human CNS malignancies.



**Rolf Bjerkvig**

# Detailed Program

ECNP2021

Wednesday, 2 June 2021

**09:00-18:30 - Exhibit Hall and ePoster viewing open**

**12:00-13:00 - Quick Pitch poster sessions** (mini oral poster presentations). See presentation overview below

- 12:00 Quick Pitch session 10: Gliomas
- Quick Pitch session 11: Tumors
- Quick Pitch session 12: Neuroinflammatory diseases
- Quick Pitch session 13: Neurodevelopmental diseases and epilepsy
- Quick Pitch session 14: Other topics

**13:00-13:45 - Plenary Lecture 4** (Nightingale Auditorium)

- 13:00 **Chair:** David Scheie, Copenhagen, Denmark  
**The invasive behavior of glioma cells in the CNS and their biological characteristics**  
Rolf Bjerkvig, Bergen, Norway

**13:45-14:00 - Break. Please visit the Exhibition Hall and ePosters**

**14:00-15:30 - Symposium 7. TDP-43 proteinopathies** (Nightingale Auditorium)

- 14:00 **Chairs:** Manuela Neumann, Tübingen, Germany, and Olaf Ansorge, Oxford, United Kingdom
- 14:05 **S7.1 Neuropathology of FTLTDP**  
Ian Mackenzie, Vancouver, Canada
- 14:35 **S7.2 Cellular and system vulnerability in ALS**  
Olaf Ansorge, Oxford, United Kingdom
- 15:05 **S7.3 (P009) Cognitive decline in amyotrophic lateral sclerosis: neuropathological substrate and genetic determinants**  
Sergi Borrego-Écija, Barcelona, Spain
- 15:13 **S7.4 (P011) Neuroanatomy of FTD: whole-brain correlations between symptoms and pathologies**  
Marta Scarioni, Amsterdam, the Netherlands
- 15:21 **S7.5 (P033) Defining and diagnosing neurodegenerative movement disorders through integrated analysis of genetics and neuropathology (MD-GAP)**  
Lesley Wu, London, United Kingdom

**14:00-15:30 - Symposium 8. Myositis - clinical, morphological and differential diagnostic highlights** (Tinderbox Hall)

- 14:00 **Chairs:** Werner Stenzel, Berlin, Germany, and Anne Schänzer, Giessen, Germany
- 14:05 **S8.1 Clinical diagnostic aspects in myositis**  
Olivier Benveniste, Paris, France
- 14:28 **S8.2 Morphological diagnostic aspects in myositis**  
Werner Stenzel, Berlin, Germany
- 14:51 **S8.3 Differential diagnostic aspects in myositis**  
Benedikt Schoser, München, Germany
- 15:14 **S8.4 (P199) NanoString technology distinguishes anti-TIF-1 $\gamma$ + from anti-Mi-2+ dermatomyositis patients**  
Josefine Radke, Berlin, Germany

# Detailed Program

ECNP2021

Wednesday, 2 June 2021

## 14:00-15:30 - Symposium 9. White matter and oligodendrocyte pathology: new insights in neurodevelopmental diseases and epilepsy (Little Mermaid Hall)

- 14:00 **Chairs:** Eleonora Aronica, Amsterdam, the Netherlands, and Karen Bonde Larsen, Copenhagen, Denmark
- 14:05 **S9.1 White matter pathology in vanishing white matter: the role of astroglial pathology**  
Marianna Bugiani, Amsterdam, the Netherlands
- 14:25 **S9.2 Myelin loss and oligodendrocyte pathology in tuberous sclerosis and other mTORopathies**  
Angelika Muehlebnner, Amsterdam, the Netherlands
- 14:45 **S9.3 White matter in temporal lobe epilepsy: clinico-pathological correlates**  
Maria Thom, London, United Kingdom
- 15:05 **S9.4 (P081) Mimicking white matter pathology in a 3D-nanofiber cell culture system derived from children with drug-resistant epilepsies**  
Victoria-Elisabeth Gruber, Vienna, Austria
- 15:13 **S9.5 (P082) DNA methylation-based classification of malformations of cortical development**  
Ingmar Blümcke, Erlangen, Germany
- 15:21 **S9.6 (P080) The antiseizure and antiepileptogenic effect of matrix metalloproteinase inhibitor IPR-179 and its potential mechanisms of action**  
Diede W. Broekaart, Amsterdam, the Netherlands

## 15:30-15:45 - NanoString Lecture 2 (Nightingale Auditorium)

- 15:30 **Understanding neuropathological disorders using GeoMx® Digital Spatial Profiler**  
Christoph Koenig, Berlin, Germany

## 15:30-15:45 - Break. Please visit the Exhibition Hall and ePosters

## 15:45-17:15 - Workshop 7. Assessment of the contributions of mixed pathologies in the ageing brain (Nightingale Auditorium)

- 15:45 **Chairs:** Colin Smith, Edinburgh, Scotland, and Irina Alafuzoff, Uppsala, Sweden
- 15:50 **W7.1 Mixed pathology in the aged demented**  
Johannes Attems, Newcastle, United Kingdom
- 16:15 **W7.2 Amygdala, a hotspot of pathology in the aged**  
Irina Alafuzoff, Uppsala, Sweden
- 16:40 **W7.3 (P037) Unique changes in gene activity in the ventral midbrain precedes dopaminergic degeneration in Parkinson's disease mouse models**  
Pierre Garcia, Dudelange/Esch-sur-Alzette, Luxembourg
- 16:48 **W7.4 (P021) Subregional severity of proteinopathies in the hippocampus of late onset Alzheimer's disease and dementia with Lewy bodies patients**  
Sonja Fixemer, Dudelange/Belval, Luxembourg
- 16:56 **W7.5 (P026) Limbic-predominant age-related TDP-43 encephalopathy (LATE) in a cohort of patients with dementia: evidence of an early phase of hippocampal sclerosis**  
Alicia Uceda Heras, Madrid, Spain
- 17:04 **W7.6 (P022) Diabetes is associated with vascular dementia, not Alzheimer's disease or Lewy body dementia**  
Keivan Javanshiri, Lund, Sweden

# Detailed Program

ECNP2021

Wednesday, 2 June 2021

## 15:45-17:15 - Workshop 8. Progress in the pathological diagnosis of pediatric and adult CNS tumors (Tinderbox Hall)

- 15:45 **Chairs:** Torsten Pietsch, Bonn, Germany, and Dominique Figarella-Branger, Marseille, France
- 15:50 **W8.1. Molecular pathology of epilepsy-related low-grade lesions**  
Tom Jacques, London, United Kingdom
- 16:10 **W8.2 Modern diagnostics of ependymal tumors**  
Dominique Figarella-Branger, Marseille, France
- 16:30 **W8.3 Differential diagnostics of primitive "embryonal" tumors**  
Torsten Pietsch, Bonn, Germany
- 16:50 **W8.4. (P118) EpiDiP.org: an open access epigenomics diagnostic resource**  
Juergen Hench, Basel, Switzerland
- 16:58 **W8.5 (P102) Establishment of Droplet Digital™ PCR (ddPCR™) for rapid molecular diagnostics of brain tumors**  
Guido Reifenberger, Düsseldorf, Germany
- 17:06 **W8.6 (P127) Identification of two main subgroups among posterior pituitary tumors associated with histology, MAPK/PI3K mutations, epigenetic regulator mutations, CNV and outcome**  
Simone Schmid, Berlin, Germany

## 15:45-17:15 - Workshop 9. B cells in inflammatory demyelinating diseases (Little Mermaid Hall)

- 15:45 **Chairs:** Hans Lassmann, Vienna, Austria, and Trevor Owens, Odense, Denmark
- 15:50 **W9.1 B-cell inflammation in MS**  
Marvin van Luijn, Rotterdam, the Netherlands
- 16:07 **W9.2 Roles of B-cells in MS and potential consequences for therapy**  
Amit Bar-Or, Philadelphia, USA
- 16:24 **W9.3 Antibody mediated autoimmune diseases of the nervous system**  
Romana Höftberger, Vienna, Austria
- 16:41 **W9.4 MOG encephalomyelitis and NMOSD – insights from animal models**  
Trevor Owens, Odense, Denmark
- 16:58 **W9.5 CD20+ T cells - a T cell disguised as a B cell**  
Marina von Essen, Copenhagen, Denmark

## 17:15-17:30 - Break. Please visit the Exhibition Hall and ePosters

## 17:30-18:30 - Free Communications 4-5-6. See presentation overview below

- Free Communication session 4: CNS tumors (2 of 2) – Nightingale Auditorium  
Free Communication session 5: Neurodegenerative and prion diseases (2 of 2) – Tinderbox Hall  
Free Communication session 6: Other topics (2 of 2) – Little Mermaid Hall



# Plenary Speakers

ECNP2021



**Berge Minassian**

## Berge Minassian

Berge A. Minassian, M.D., is a Professor in the Departments of Pediatrics and Neurology at UT Southwestern Medical Center.

Dr. Minassian is a pediatric neurologist whose clinical specialties are epilepsy, neurodegenerative diseases, and neurogenetic conditions. He is Chief of Child Neurology at UT Southwestern and he also leads the Neurosciences Center at Children's Health in Dallas. He serves on the faculty of the Children's Medical Center Research Institute at UT Southwestern, as well.

Dr. Minassian has been active in neurogenetics research for his entire career. Two of his primary interests have been Lafora disease, for which his lab discovered the genes, and adult polyglucosan body disease.

He has published more than 120 scholarly articles and authored or contributed to 10 books. Dr. Minassian is a Fellow (Neurology) of the Royal College of Physicians and Surgeons of Canada and a founding member of the American Academy of Neurology's Neurogenetics Section. Prior to joining the UT Southwestern faculty in 2016, he was a Professor of Neurology at the University of Toronto, a pediatric neurologist at Toronto's Hospital for Sick Children, and a senior scientist in genetics and genome biology at the Hospital for Sick Children Research Institute.

Dr. Minassian earned his medical degree at McGill University Faculty of Medicine and performed a residency in adult neurology at the Veterans Administration West Los Angeles Medical Center. He then completed a clinical fellowship in pediatric neurology and epileptology, as well as postdoctoral research fellowships in both molecular genetics and molecular neurogenetics at the University of Toronto's Hospital for Sick Children.

Dr. Minassian's many professional honors include the Jacob's Ladder 2014 Norman Saunders International Research Prize for Outstanding Scientist, the American Academy of Neurology 2007 Dreifuss-Penry Epilepsy Award, the Canadian Paediatric Society 2008 Sanofi Pasteur Research Award, and the American Epilepsy Society 1996 Young Investigator Award.

# Plenary Speakers

ECNP2021


## Piero Parchi

Piero Parchi is Associate Professor of Neurology and Director of the Program on the Neuropathology of Neurodegenerative diseases at the Institute of Neurological Sciences of Bologna, Italy.

Professor Parchi received his M.D. and specialty titles in Neurology and Anatomic Pathology from the University of Bologna and his Ph.D. in Neurosciences from the University of Verona, Italy.

Since 1993 he has primarily conducted his research studying the molecular basis of phenotypic variability in human prion disease. The results of his studies have significantly contributed to the characterization of human prion strains and the current classification of Creutzfeldt-Jakob disease variants.

Since 2015 he has expanded his research interests to the clinical validation of pathology-driven biofluid biomarkers for the early diagnosis of neurodegenerative diseases exploiting novel ultrasensitive seeding assays to detect misfolded prion and prion-like protein amyloids.



**Piero Parchi**

# Detailed Program

ECNP2021

## Thursday, 3 June

**09:00-18:30 - Exhibit Hall and ePoster viewing open**

**11:30-13:00 - ISN Business Meeting (For ISN Council & Executive Committee only, upon invitation)**

**12:00-13:00 - Quick Pitch poster sessions** (mini oral poster presentations). See presentation overview below

- 12:00 Quick Pitch session 15: Gliomas
- Quick Pitch session 16: Tumors
- Quick Pitch session 17: Neuroinflammatory diseases
- Quick Pitch session 18: Neurodegenerative diseases and leukoencephalopathies

**13:00-13:45 - Plenary Lecture 5** (Nightingale Auditorium)

**Chair:** Joachim Weis, Aachen, Germany

**Polyglucosan storage in muscle and brain - disease entities and pathogenesis**

Berge Minassian, Dallas, USA

**13:45-14:00 - Break. Please visit the Exhibition Hall and ePosters**

**14:00-15:30 - Symposium 10. Neuropathology training, courses and examination (EFN) in Europe**  
(Tinderbox Hall)

- 14:00 **Chairs:** Tibor Hortobágyi, Debrecen/Szeged, Hungary, and Wilfred den Dunnen, Groningen, the Netherlands
- 14:05 **Round-table discussion, with lecturers and participants of Euro-CNS courses, examiners and candidates of EFN examinations.** The symposium will cover neuropathology training across Europe - the current situation and challenges of the future.

**14:00-15:30 - Symposium 11. Intratumoral heterogeneity** (Nightingale Auditorium)

- 14:00 **Chairs:** Rolf Bjerkvig, Bergen, Norway, and Hrvoje Miletic, Bergen, Norway
- 14:05 **S11.1 Longitudinal molecular trajectories of diffuse glioma in adults**  
Roel Verhaak, Farmington, Connecticut, USA
- 14:22 **S11.2 Epigenomic contribution to glioblastoma heterogeneity**  
Adelheid Woehrer, Vienna, Austria
- 14:39 **S11.3 Role of intrinsic tumor plasticity and microenvironment in creating intratumoral heterogeneity in glioblastoma**  
Anna Golebiewska, Luxembourg, Luxembourg
- 14:56 **S11.4 Brain tumor invasion into the CNS - mechanisms of action**  
Rolf Bjerkvig, Bergen, Norway
- 15:13 **S11.5 (P095) Subependymoma of the posterior fossa may progress to ependymoma: role of TERT mutation, loss of chromosome 6 and methylome alterations**  
Christian Thomas, Münster, Germany
- 15:21 **S11.6 (P173) Targeted gene expression, TERT mutation and loss of H3K27me3 in WHO grade III meningiomas across recurrences**  
Andrea Maier, Copenhagen, Denmark

# Detailed Program

ECNP2021

Thursday, 3 June

## 14:00-15:30 - Symposium 12. Dynamic aspects of amyloid- $\beta$ (Little Mermaid Hall)

**Chairs:** James Nicoll, Southampton, United Kingdom, and Zane Jaunmuktane, London, United Kingdom

- 14:05 **S12.1 The relationship between spreading and maturation of amyloid- $\beta$  pathology in AD**  
Dietmar Thal, Leuven, Belgium
- 14:25 **S12.2 Evidence for the person-to-person transmissibility of amyloid- $\beta$**   
Zane Jaunmuktane, London, United Kingdom
- 14:45 **S12.3 Removal of amyloid- $\beta$  from the brain by immunotherapy**  
James Nicoll, Southampton, United Kingdom
- 15:05 **S12.4 (P017) Alzheimer's disease neuropathological change and loss of neuropil and matrix in idiopathic normal pressure hydrocephalus, a model of Alzheimer's disease**  
Sylwia Libard, Uppsala, Sweden
- 15:13 **S12.5 (P020) The coarse-grained plaque: a divergent A $\beta$  plaque-type in early-onset Alzheimer's disease**  
Baayla Boon, Amsterdam, the Netherlands

15:30- 15:45 - Break. Please visit the Exhibition Hall and ePosters

## 15:45-17:15 - Symposium 13. COVID-19 and neuropathology (Nightingale Auditorium)

- 15:45 **Chairs:** Safa Al-Sarraj, London, United Kingdom, and Markus Glatzel, Hamburg, Germany
- 15:50 **S13.1 Brain pathology of COVID-19**  
Markus Glatzel, Hamburg, Germany
- 16:13 **S13.2 COVID-19 encephalitis; the pathological evidence**  
Safa Al-Sarraj, London, United Kingdom
- 16:36 **S13.3 (P234) Olfactory transmucosal SARS-CoV2 invasion as port of central nervous system entry in COVID-19**  
Jenny Meinhardt, Berlin, Germany
- 16:46 **S13.4 (P231) Post-infectious myopathy related to COVID-19**  
Leila Chimelli, Rio de Janeiro, Brazil
- 16:45 **Panel discussion**

*The Symposium is supported by the International Society of Neuropathology (ISN)*

17:15-17:30 - Break. Please visit the Exhibition Hall and ePosters

## 17:30-18:15 - Plenary Lecture 6 (Nightingale Auditorium)

**Chair:** Eva Løbner Lund, Copenhagen, Denmark

**Deciphering phenotypic variability and transmission properties of human prion diseases**  
Piero Parchi, Bologna, Italy

## 18:15-18:30 - Best ePoster Prizes and Closure

*The program may be subject to change*

# Free Communication sessions

ECNP2021

(7 presentations of 5 minutes talk + 3 minutes for Q&A)

## Tuesday 2 June - Free Communication session 1. CNS tumors (1 of 2)

Chairs: David Scheie, Helle Broholm

FC 1.1	P106. MYB/MYBL1-altered gliomas subdivide into several groups that are morphologically and epigenetically distinct and have gene fusions of MYBL1 or MYB	Annika Wefers
FC 1.2	P144. TGF- $\beta$ activates pericytes via induction of the epithelial to mesenchymal transition protein SLUG in glioblastoma	Michel Mittelbronn
FC 1.3	P158. Analysis of chromosomal abnormalities and of cell cycle genes alterations in a series of 48 chordomas	Homa Adle-Biassette
FC 1.4	P166. Macroscopic stimulated Raman spectroscopy: histologic verification of a classifier discriminating meningioma and dura mater	Finn Jelke
FC 1.5	P168. Re-assessing the prognostic value of Ki-67 and p53 in recurrent and non-recurrent PitNETs	Annalize Odamtten
FC 1.6	P182. Implementation of DNA methylation arrays in pediatric brain tumors classification	Sabrina Rossi
FC 1.7	P184. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification	Christian Mirian

## Tuesday 2 June - Free Communication session 2. Neurodegenerative and prion diseases (1 of 2)

Chairs: Eva Løbner Lund, Thomas Brännström

FC 2.1	P002. The effect of atherosclerosis in the neurovascular unit	Monica A Rebollar Guagnelli
FC 2.2	P015. Contribution of neuropathology for the diagnosis and surveillance of prion diseases in Brazil - case series from 2005 - 2020	Leila Chimelli
FC 2.3	P027. Multinodular vacuolating neuronal tumor arising in the setting of corticobasal degeneration shows relative exclusion of disease-associated tau immunoreactivity	Andrew Gao
FC 2.4	P028. Fulminant corticobasal degeneration mimicking autoimmune brainstem encephalitis.	Ricardo Taipa
FC 2.5	P031. Pathogenic alpha-synuclein is present in the kidneys of Lewy body disease patients	Liam Chen
FC 2.6	P032. Disease-linked IFNAR1C291* mutation in familial Parkinsonian disorders leads to mitochondrial dysfunction and proteinopathy	Lluís Riera Ponsati

# Free Communication sessions

ECNP2021

## Tuesday 2 June - Free Communication session 3. Other topics (1 of 2)

Chairs: Martin Wirenfeldt Nielsen, Ellen Antal

FC 3.1	P058. Autoimmune global hippocampal amnesia as a manifestation of AMPAR encephalitis and associated neuropathological findings	Gerda Ricken
FC 3.2	P065. Neuronal activation and modulation of necroptosis signaling in progressive multiple sclerosis	Carmen Picon
FC 3.3	P068. CSF proteome in multiple sclerosis subtypes related to brain lesion transcriptomes	Maria Louise Elkjær
FC 3.4	P200. Spinal encoding of motor deficits induced by a unilateral brain injury: analysis of hindlimb motor responses	Marlene Storm Andersen
FC 3.5	P204. Muscle biopsy role in identification of McArdle disease prior to genetic test	Renato Oliveira
FC 3.6	P232. Spectrum of neuropathological findings in a series of 13 COVID-19 patients	Anne Sieben
FC 3.7	P233. SARS-CoV-2 neuropathology: evidence from a post-mortem autopsy series in Padova, Italy	Aron Emmi

## Wednesday 2 June - Free Communication session 4. CNS tumors (2 of 2)

Chairs: Maria Gardberg, Bjarne Winther Kristensen

FC 4.1	P100. Myxopapillary ependymomas comprise two subgroups with distinct age, histomorphology, DNA methylation, gene expression, and clinical outcome	Ulrich Schüller
FC 4.2	P108. Beyond IDH1 R132H mutation: a Spanish cohort of non-canonical IDH mutant gliomas	Elena Martinez-Saez
FC 4.3	P117. Retrospective prognostic and diagnostic impact of next generation sequencing and new molecular criteria in adult glioma patients	Danny Mortensen
FC 4.4	P120. The coding and non-coding landscape of subependymal giant cell astrocytomas associated with tuberous sclerosis complex	Angelika Mühlebner
FC 4.5	P131. Drug repurposing screen reveals glioblastoma cell line susceptibility to statins	Dylan Scott Lykke Harwood
FC 4.6	P153. Comprehensive molecular profiling of paediatric CNS tumors - experience from a single neuropathology centre	Zita Reisz
FC 4.7	P191. Valproic acid modifies total DNA methylation level and attenuates temozolomide effect in glioblastoma cell lines	Anna-Maria Barciszewska

# Free Communication sessions

ECNP2021

## Wednesday 2 June - Free Communication session 5. Neurodegenerative and prion diseases (2 of 2)

Chairs: Jens Pahnke, Elisabeth Englund

FC 5.1	P003. Pathological background of aphasia associated with neurodegenerative diseases	Mari Yoshida
FC 5.2	P004. Neuropathologic diversity in four tauopathy cases with duplication of the MAPT gene	Susana Boluda
FC 5.3	P007. Atypical frontotemporal lobar degeneration with bizarre glia, 4 > 3 repeat astroglia and distinct TDP43 inclusions. Report of two cases	Iban Aldecoa
FC 5.4	P008. A de novo p.S320F (c959C>T) microtubule-associated protein tau gene mutation causes a Pick's disease-like pathology with a predominant 3-repeat-tau component	Laura Molina Porcel
FC 5.5	P012. Using an induced pluripotent stem cell model of frontotemporal dementia to identify altered metabolic profiles in patient-derived neurons	Gunnar Hargus
FC 5.6	P038. Assessment of the endothelial cells to pericytes ratio in the brain capillary wall in rats with experimental dementia	Yevgeniya Zorenko
FC 5.7	P040. Replacing deficient microglia in a zebrafish model of a childhood human leukodystrophy as a new therapy	Holly A Rutherford
FC 5.8	P014. Molecular characterization of the Danish Prion Diseases Cohort with special emphasis on rare and unique cases	Eva Løbner Lund

## Wednesday 2 June - Free Communication session 6. Other topics (2 of 2)

Chairs: Christian Beltoft Brøchner, Martin Wrenfeldt Nielsen

FC 6.1	P063. Substantial 'ependymal-in' gradient of thalamic damage in progressive multiple sclerosis	Roberta Magliozzi
FC 6.2	P072. Systematic classification of spina bifida phenotypes	Kim Hannah Schindelmann
FC 6.3	P073. Neuropathology of genetically defined malformations of cortical development - a systematic literature review	Stefanie Brock
FC 6.4	P079. Iron accumulation and dysregulated iron metabolism after status epilepticus and temporal lobe epilepsy	Till S. Zimmer
FC 6.5	P086. Cortical neuronal hypertrophy and MTOR pathway activation in autonomic brain regions in SUDEP	Smriti Patodia
FC 6.6	P212. The potential for digitalization of frozen sections - results from a workflow analysis	Marina Fotteler
FC 6.7	P222. Histopathological changes and CSF findings after natalizumab therapy for multiple sclerosis	Darius Häusler

# Quick Pitch Sessions

ECNP2021

## Quick Pitches

(10 short oral poster presentations of 3 minutes each followed by 30 minutes of discussion time)

### Monday 31 May - Quick Pitch 1. Gliomas

Chairs: Pieter Wesseling, Signe Regner Michaelsen

QP 1.1	P088. Unexpected presentation of an IDH-mutant glioblastoma at autopsy	Cheryl Coulter
QP 1.2	P089. PAX2 immunoexpression in adult glioblastoma	Montserrat Arumí-Uría
QP 1.3	P090. The evaluation of palisading necrosis, vascular endothelial proliferation morphology using digital pathology systems and their relations with prognosis	Neşe Yeldir
QP 1.4	P107. Prognostic role of the proliferation marker Ki-67 in glioblastomas taking tumor microenvironment, MGMT promoter methylation and post-surgical treatment into account	Rikke Hedegaard Dahlrot
QP 1.5	P109. Stem cell marker ALDH1A3 is not involved in mediating radiochemoresistance while RSL-3 induces ferroptotic cell death in C6 glioma model	Julian Allgeier
QP 1.6	P110. Differential expression of genes modulating RNA-methylation in low- and high-grade glioma	Simon Deacon
QP 1.7	P112. The role of aldehyde dehydrogenase 1 (ALDH1) in the treatment of glioma cells with cold atmospheric plasma (CAP)	Alicia Gantzkow
QP 1.8	P113. Prognostic impact of CDKN2A/B genes deletion and MGMT promoter gene deletion on diffuse astrocytic tumors	Maria Fernanda Ruiz
QP 1.9	P114. Utility of the new molecular platforms in the study of complex pediatric brain tumors	Miguel Idoate
QP 1.10	P116. Desmoplastic infantile astrocytoma/ganglioglioma; histomorphological and molecular analysis of 8 cases	Ibrahim Kulac



# Quick Pitch Sessions

ECNP2021

## Monday 31 May - Quick Pitch 2. Tumors

Chairs: Dominique Figarella-Branger, Andrea Maier

QP 2.1	P169. SHH pathway proteins expression in germ cell tumors including intracranial cases	Ewa Izycka-Swieszewska
QP 2.2	P170. Histopathological and clinical features as prognostic factors of atypical meningiomas	Pinar Karabagli
QP 2.3	P171. Atypical teratoid rhabdoid tumor of lateral ventricle in an adult	Pinar Karabagli
QP 2.4	P172. The epidemiology of patients undergoing meningioma resection in Auckland, New Zealand, 2002 to 2011	Clinton Turner
QP 2.5	P128. Integrated analysis of molecular alterations and immune cell infiltration in primary and recurrent glioblastomas	Jeanette Krogh Pedersen
QP 2.6	P174. The integrated diagnosis of medulloblastoma in a middle-aged, pregnant patient: a case report	Clare McGenity
QP 2.7	P175. Functional analysis of a novel CTNNB1 mutation in pediatric medulloblastoma (MB)	Laura Zaldumbide
QP 2.8	P176. Proliferative index like a prognostic factor for medulloblastoma. A useful tool in low and middle-income countries	Sandro Casavilca-Zambrano
QP 2.9	P177. Chordoma arising from benign notochordal tumor: a case report	Maryam Almurshed
QP 2.10	P178. Rare thyroid transcription factor 1-positive tumors of posterior pituitary gland: experience of a single institution in twenty years	M. Victoria Zelaya

## Monday 31 May - Quick Pitch 3. Neurodegenerative diseases

Chairs: Eva Løbner Lund, Atul Anand

QP 3.1	P016. Biochemical variants of beta-amyloid and their association with hyperphosphorylated tau in brain biopsies from subjects with idiopathic normal pressure hydrocephalus	Sylwia Libard
QP 3.2	P025. Primary Age-Related Tauopathy (PART) in a Finnish population-based study of the oldest old (Vantaa 85+)	Sara Savola
QP 3.3	P025.5. Persistent oxidative DNA damage alters the neuronal transcriptome and impacts cell cycle regulation and mitochondrial function	Irina Vazquez Villasenor
QP 3.4	P035. Alpha-synuclein-induced pathologies in brain and gut by curli and a fibre-deprived diet in a transgenic mouse model of Parkinson's disease	Kristopher J Schmit
QP 3.5	P036. Alpha-Synuclein and gene expression regulation: insights from in vivo and in vitro models	Alessia Sciortino
QP 3.6	P039. MIMO2 (A Moringa oleifera leaf derivative): a possible antidote to neurodegeneration	Olumayowa Igado
QP 3.7	P026Z. Lemur tyrosine kinase 2 (LMTK2) level inversely correlates with phospho-tau in neuropathological stages of Alzheimer's disease	Tibor Hortobágyi
QP 3.8	P026Z.1. Analysis of lemur tyrosine kinase-2 expression in neurodegenerative dementias	Tibor Hortobágyi
QP 3.9	P196. Tau pathology in Niemann-Pick type C follows Braak's Alzheimer's disease staging - insights from an 18-year-old patient autopsy	Ricardo Taipa
QP 3.10	P215. BRAIN UK: Accessing NHS diagnostic archives for neuroscience research	James Nicoll

# Quick Pitch Sessions

ECNP2021

## Monday 31 May - Quick Pitch 4. Neuroinflammatory diseases

Chairs: Martin Lammens, Rikke Sick Andersen

QP 4.1	P060. Diagnostic conundrum in a rare case of isolated CNS lymphomatoid granulomatosis	Ashirwad Merve
QP 4.2	P061. Neuronal diversity in the multiple sclerosis brain by single-nuclear RNA sequencing	Kristof Egervari
QP 4.3	P062. The extent and distribution of fibrinogen deposition in progressive MS correlate with meningeal and choroid plexus inflammation and lesion activity	Roberta Magliozzi
QP 4.4	P064. NRF2, a promising target to reduce microglial reactivity in PD	Tony Heurtaux
QP 4.5	P069. Is involvement of visual and craniobulbar pathway in rabies encephalitis the anatomical pathway for hydrophobia?	Anita Mahadevan
QP 4.6	P070. A case of progressive multifocal leukoencephalopathy with HIV positive	Yingxin Yu
QP 4.7	P208. Hypothalamitis: a novel autoimmune endocrine disease. A literature review and case report	Aydin Sav

## Tuesday 1 June - Quick Pitch 5. Gliomas

Chairs: Bjarne Winther Kristensen, Atul Anand

QP 5.1	P087. A case report of a novel NTRK-gene fusion in pleomorphic xanthoastrocytoma	Melek Ahmed
QP 5.2	P091. Total DNA methylation and 8-oxo-deoxyguanosine as markers of DNA damage and tumor malignancy in gliomas	Anna-Maria Barciszewska
QP 5.3	P092. Postoperative prognostic nomogram for adult grade II/III astrocytoma in Chinese Han people	Lijie Wang
QP 5.4	P093. Genetic and environmental determinants of O6-methylguanine DNA-methyltransferase (MGMT) gene methylation: a 10-year longitudinal study of Danish twins	Lijie Wang
QP 5.5	P094. The impact of time from surgery to radiochemotherapy on overall survival in patients with newly diagnosed glioblastoma	Kasper Selvig Jacobsen
QP 5.6	P096. Incidence, clinicopathologic and genetic characteristics of mismatch repair gene mutated glioblastomas	Yoon Ah Cho
QP 5.7	P097. Distribution and characterization of IDH1 G105G (rs11554137) SNP in a consecutive series of adult diffuse gliomas	Luca Bertero
QP 5.8	P098. Alterations of RECQL4 and related helicases in glial neoplasms	Sarra Belakhoua
QP 5.9	P099. The multi-target small-molecule inhibitor SB747651A shows in vitro and in vivo anticancer efficacy in glioblastomas	Arnon Møldrup Knudsen
QP 5.10	P101. Long-term survival and extracranial spread in a patient with a rare variant of malignant glioma	Antonia Gabrielsen

# Quick Pitch Sessions

ECNP2021

## Tuesday 1 June - Quick Pitch 6. Tumors I

Chairs: Guido Reifenberger, Jesper Dupont Ewald

QP 6.1	P161. Methylation signature of atypical meningiomas	Sverre Helge Torp
QP 6.2	P162. Epidemiology and outcomes of patients with primary central nervous system tumors managed at the King Hussein Cancer Center, 2006–2019	Maysa Al-Hussaini
QP 6.3	P163. DNA methylation analysis reveals epigenetic regulation of neural differentiation in AT/RTs	Kirsi Granberg
QP 6.4	P164. Multiple site biopsies is necessary for diagnosis of primary CNS lymphoma	Chenhui Mao
QP 6.5	P165. Molecular profile in Intermediate-grade melanocytic neoplasm. Comparative series with Uveal melanomas	Carolina Montecino Romanini
QP 6.6	P167. Raman spectroscopy-based tumor entity differentiation of cryopreserved and formalin-fixed samples	Giulia Mirizzi
QP 6.7	P187. Confocal laser endomicroscopy: the distribution of fluorescent sodium in ex vivo samples of brain tumors	Franziska Ganster
QP 6.8	P188. Intermediate grade melanocytoma in the context of meningeal melanocytosis - discussion of a difficult case	Diana Pasov
QP 6.9	P189. Expression and gene regulation of calbindin in meningioma	Lukas Friedrich
QP 6.10	P190. An undergoing tale of two techniques: digital slide analysis versus pathologists visual scoring in interpreting Ki-67 index in meningiomas	Servet Güreşçi

## Tuesday 1 June - Quick Pitch 7. Tumors II

Chairs: Adelheid Wöhrer, Line Buchwald

QP 7.1	P140. The molecular study of the MMR deficient high grade gliomas	Hyunhee Kim
QP 7.2	P141. Phospholipase C $\beta$ 1: a new potential prognostic biomarker in glioblastoma multiforme	Maria Vittoria Marvi
QP 7.3	P144Z. Pleomorphic xanthoastrocytoma - a heterogeneous entity in which pTERT mutations prognosticate shorter survival	Azedeh Ebrahimi
QP 7.4	P144Z.1. Immunohistochemical correlates of PARP1 with ATRX and p53 in glioblastoma	Tibor Hortobágyi
QP 7.5	P144Z.2. Molecular subtype dependent expression of PARP1 in glioblastoma - a bioinformatic analysis of the TCGA dataset	Tibor Hortobágyi
QP 7.6	P190Z.2. Intracranial mesenchymal chondrosarcoma: a rare histopathological entity	Joana Vitor
QP 7.7	P190Z. Predictive immunohistochemical markers in meningiomas	Tibor Hortobágyi
QP 7.8	P185. Preclinical cerebral cryoablation: feasibility, safety and efficacy in non-tumor bearing pigs	Irena Jankovic
QP 7.9	P193. PIK3CA mutant metastatic breast cancer presenting as a meningeal syndrome. Case report	Alejandro Brito García
QP 7.10	P148. Metastatic lung adenocarcinoma with incidental finding meningioma in a frontal lobe in a young patient	Pinar Cakmak
QP 7.11	P225. Fluorescence labeled PARP inhibitor PARPi-FL for intraoperative identification of tumor cells in human glioblastomas - a pilot study	Nicolas Pensel

# Quick Pitch Sessions

ECNP2021

## Tuesday 1 June - Quick Pitch 8. Neuromuscular and storage diseases

Chairs: Joachim Weis, Rikke Sick Andersen

QP 8.1	P195. Findings at neuroautopsy in a patient with Hurler-Scheie syndrome	Eric Goold
QP 8.2	P197. Mitochondrial dysfunction associated with CLN1 Knock-Out in SH-SY5Y neuronal-like cells	Francesco Pezzini
QP 8.3	P198. Acquired TTR amyloid neuropathy - insights from a nerve biopsy cohort study	Miguel Pinto
QP 8.4	P201. ACTA1-related myopathy with focal myofibrillar pathology and cytoplasmic bodies	Miguel Pinto
QP 8.5	P202. Mitochondrial myopathy: a case report	Camila Campos
QP 8.6	P203. Mitochondrial disorders in adults: histopathological and ultrastructural correlations in Polish patients with nuclear DNA mutations	Biruta Kierdaszuk
QP 8.7	P226. Digital pathology in the muscle biopsy services during the COVID-19 pandemic: a large UK centre experience	Ashirwad Merve

## Tuesday 1 June - Quick Pitch 9. Other topics

Chairs: Johannes Hainfellner, Vilde Pedersen

QP 9.1	P230Z. Altered matrilin-2 and tenascin-C expression in corneal diseases with reduced transparency	Tibor Hortobágyi
QP 9.2	P209. Application of the new "Digital Brain" platform of the archive of human brains in scientific research on Alzheimer's disease (AD)	Anna Mietelska-Porowska
QP 9.3	P001. Cortical raspberries – a sign of compromised perfusion?	Henric Ek Olofsson
QP 9.4	P213. Recurrent acute ischaemic "stroke" from fibrocartilaginous cerebral emboli – a case report	Fouzia Ziad
QP 9.5	P230. Astrocyte-oligodendrocyte-microglia crosstalk in astrocytopathies	Dieuwke De Waard
QP 9.6	P228. Plasticity of cholinergic system in the spinal cord following traumatic brain injury	Jonas Larsen
QP 9.7	P013. Regional differences in neuroinflammation-associated gene expression in the brain of sporadic Creutzfeldt-Jakob disease patients	Ausrine Areskeviciute
QP 9.8	P235. Histological characteristics and proliferative activity of glioblastomas in the central and peripheral regions of the tumor	Olga Vorobeva
QP 9.9	P236. Piloid-like changes after combination therapy in glioblastoma with prominent gemistocytic component: a case report	Olga Vorobeva
QP 9.10	P237. Heterogeneity in pediatric hemispheric high grade glioma: genetic landscape at primary and recurrence tumor	Manila Antonelli

# Quick Pitch Sessions

ECNP2021

## Wednesday 2 June - Quick Pitch 10. Gliomas

Chairs: Toumas Rauramaa, Line Buchwald

QP 10.1	P119. Deeper insight into intratumoral heterogeneity by MRI and PET-guided stereotactic biopsies from glioblastoma patients	Atul Anand
QP 10.2	P121. Microscopic features of polymorphous low-grade neuroepithelial tumor of the young (PLNTY) in patient with epilepsy	Maciej Ciołkowski
QP 10.3	P122. Remodeling of the glioblastoma immune landscape by Smac mimetic GDC-0152	Emmanuel Snacel-Fazy
QP 10.4	P124. Differential expression of microglia/macrophage markers, Iba1 and CD163 in glioblastoma	Christina Loh
QP 10.5	P125. Exploration of DNA methylation patterns in glioblastoma reprogrammed microglial cells	Lorraine Richart
QP 10.6	P126. Invasion promoting genes in glioblastoma cells identified by a genome-wide CRISPR/Cas9 activation screen	Tanja Müller
QP 10.7	P129. Expression and prognostic value of Jumonji domain-containing protein 6 (JMJD6) in a population-based cohort of IDH-wildtype glioblastoma patient	Ann Mari Rosager
QP 10.8	P130. A simplified integrated molecular and immunohistochemistry-based algorithm for glioblastoma subtyping on paraffin embedded tissue sections	Pietro Luigi Poliani
QP 10.9	P142. Clinico-imagistic features of glioblastomas at the pathology department of the SCJU Târgu Mureș	Sipos Tamas
QP 10.10	P143. Syntenin is highly expressed in IDH-wildtype glioblastoma but not associated with prognosis	Jesper Dupont Ewald

## Wednesday 2 June - Quick Pitch 11. Tumors

Chairs: Sverre Torp, Andrea Maier

QP 11.1	P145. Concurrent EBV positive CNS diffuse large B-cell lymphoma and peripheral T-cell lymphoma, NOS	Lorraina Robinson
QP 11.2	P146. Intracranial myxoid mesenchymal tumor with FET/CREB fusion - a novel entity causing diagnostic challenges in neuropathology	Zita Reisz
QP 11.3	P214. Importance of molecular diagnosis of central nervous system tumors and legal implications in	Brazil Camila Campos
QP 11.4	P149. Hypothalamic hamartoma: a case report	Nagihan Yalçın
QP 11.5	P179. Sonic hedgehog and Wnt signaling drives murine ocular lesions reminiscent of intraocular medulloepithelioma	Matthias Dottermusch
QP 11.6	P180. Axonal density in prostate cancer - morphological and quantitative study	Ewa Izycka-Swieszewska
QP 11.7	P181. Copenhagen meningioma grading	Jeppe Lohfert Haslund-Vinding
QP 11.8	P183. The Ki-67 proliferation index as marker of time to recurrence in intracranial meningioma	Christian Mirian Larsen
QP 11.9	P186. Prognostic value of the Ki-67 index in childhood medulloblastoma	Maysa Al-Hussaini
QP 11.10	P190Z.1. Immunohistochemical correlates of TP53 somatic mutations in brain tumors	Tibor Hortobágyi

# Quick Pitch Sessions

ECNP2021

## Wednesday 2 June - Quick Pitch 12. Neuroinflammatory diseases

Chairs: Romana Höftberger, Signe Regner Michaelsen

QP 12.1	P041. Innate signaling in the CNS prevents demyelination in a focal EAE model	Magdalena Dubik
QP 12.2	P050. Histopathological analysis of T-cell infiltration and chemokine at the human brain infarcts	Masahiro Shijo
QP 12.3	P051. Extracellular vesicles from plasma of hyperammonemic rats induce neuroinflammation and motor incoordination in control rats	Paula Izquierdo-Altarejos
QP 12.4	P052. SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of MS patients	Helena Radbruch
QP 12.5	P053. Temporal and spatial patterns of inflammation and oxidative injury in traumatic human spinal cord injury (SCI)	Carmen Schwaiger
QP 12.6	P054. Neuropathology and magnetic resonance imaging characteristics in autoimmune glial fibrillary acidic protein meningo-encephalomyelitis	Verena Endmayr
QP 12.7	P055. Biopsy proven cerebral sparganosis: a case report	Chenhui Mao
QP 12.8	P056. Rifaximin prevents motor incoordination in rats with mild liver damage by preventing immune cell infiltration and neuroinflammation in the cerebellum	Gergana Ivaylova
QP 12.9	P057. The serine protease HTRA1 increases in the CSF in multiple sclerosis and correlates with disease progression and disability	Simone Hjärtesen
QP 12.10	P059. Paraneoplastic cerebellar degeneration with anti-P/Q-type VGCC and anti-Yo autoantibodies: a comparative study	Michael Winklehner

## Wednesday 2 June - Quick Pitch 13. Neurodevelopmental diseases and epilepsy

Chairs: Homa Adle-Biassette, Vilde Pedersen

QP 13.1	P071. Severe telencephalic malformations in an infant carrying a de novo pathogenetic variant in ATP1A3	Alessandro Simonati
QP 13.2	P071Z. Transient boundaries and compartments of developing human fetal striatum: the role of lecticans and tenascins	Sanja Darmopil
QP 13.3	P074. Cerebral abnormalities in spina bifida: a neuropathological study	Fabienne Paschereit
QP 13.4	P075. Limited anatomical and microscopic findings in a case of Wolf-Hirschhorn syndrome highlight the spectrum of disease	Joshua Klonoski
QP 13.5	P076. Temporal changes in the brain in neonatal hydrocephalic mice: structural and neurobehavioural findings	Omowumi Femi-Akinlosotu
QP 13.6	P077. Neuropathological findings in a patient with Fowler syndrome surviving into adulthood: an autopsy report	Melek Ahmed
QP 13.7	P078. Loss of capillary low-density lipoprotein receptor-related protein 1 expression in the hippocampus of temporal lobe epilepsy and Alzheimer's Disease patients	Annemieke Rozeboom
QP 13.8	P083. Increased expression of complement components in tuberous sclerosis complex and focal cortical dysplasia 2b brain lesions	Mark J. Luinenburg
QP 13.9	P083Z. The histoarchitectonic glycosylation pattern of diffused and perineuronal condensed extracellular matrix in hippocampal sclerosis	Barbara Sitaš
QP 13.10	P084. Histopathological findings in brain tissue of patients with pharmacoresistant epilepsy	Dimitar Metodiev
QP 13.11	P085. Ectopic neurons in deep white matter of the temporal lobe: histopathological assessment in epilepsy - a case-controlled retrospective study	Adarsh Aji

# Quick Pitch Sessions

ECNP2021

## Wednesday 2 June - Quick Pitch 14. Other topics

Chairs: Christian Mawrin, Nicolai Stilling Schou

QP 14.1	P221. Postmortem neuropathologic examination of a 5-case series of CAR T cell treated patients	Ivan Archilla
QP 14.2	P219. Application of Raman spectroscopy for detection of histologically distinct areas in formalin-fixed paraffin-embedded (FFPE) glioblastoma	Gilbert Georg Klamming
QP 14.3	P216. Bacterial lipopolysaccharide (LPS) in cavernomas. An immunohistochemical study	Emilia Saari
QP 14.4	P217. Lipopolysaccharide is expressed in the inflammatory cells of brain AVMs and associates with COX2 expression	Sara Keränen
QP 14.5	P220. Conventional diagnostic methods and ex vivo confocal laserendomicroscopy (CLE) in neuropathology: a comparison	Johann Bierlein
QP 14.6	P224. Single injection of Gadolinium based contrast agents does not induce significant alterations of gene expression in rodent cerebellum	Astrid Jeibmann
QP 14.7	P218. Vanadium, an environmental pollutant, induces oxidative damage in the brain following acute exposure	Oluwabusayo R Folarin

## Thursday 3 June - Quick Pitch 15. Gliomas

Chairs: Felix Sahn, Jesper Dupont Ewald

QP 15.1	P103. BCAS1 defines a heterogenous population in 1p/19q codeleted glioma	Maria Jose Ulloa-Navas
QP 15.2	P104. Immunohistochemical analysis of IDH1 and p53 in glioblastomas and its relationship to the mTOR pathway	Pinar Cakmak
QP 15.3	P105. A small molecular assessment of tumors classified as diffuse astrocytoma at Aalborg University Hospital from 2004 to 2018	Marianne Schmidt Ettrup
QP 15.4	P132. The tumor microenvironment in early recurrent glioblastomas is enriched for pro-tumorigenic M2 microglia/macrophages	Arnon Møldrup Knudsen
QP 15.5	P133. Nivolumab and bevacizumab for recurrent glioblastoma; a translational trial	Simone Bendix Maarup
QP 15.6	P134. DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas	Sandra Ferreyra Vega
QP 15.7	P136. Comparison of preoperative neutrophil-to-lymphocyte ratio with survival, histological properties, and immunohistochemical parameters in glioblastomas	Pinar Cakmak
QP 15.8	P137. High mitochondrial DNA copy number is associated with better prognosis in young adult glioblastoma	Audrey Rousseau
QP 15.9	P138. Automated analysis of the heterogeneity of histological glioblastoma slides using neural networks	Georg Prokop
QP 15.10	P139. Expression of glucose transporters GLUT 1, 3, and 4 in glioblastoma	Ewa Izycka-Swieszewska

# Quick Pitch Sessions

ECNP2021

## Thursday 3 June - Quick Pitch 16. Tumors

Chairs: Tom Jacques, Line Buchwald

QP 16.1	P147. Immunodeficiency-associated lymphoproliferative disorders affecting the central nervous system	M. Victoria Zelaya
QP 16.2	P150. Molecular pathological insights in children treated for medulloblastoma and CNS-PNET in Oslo from 2005-2017	Pitt Niehusmann
QP 16.3	P151. Metaplastic lipidized meningioma in a patient harbouring CHEK2 germline VUS. Case report and review of the literature	Isabel Betancor Fernández
QP 16.4	P152. Anaplastic ependymoma of spine in young adult male	Vanaja Muthurajah
QP 16.5	P154. Intracranial myxoid mesenchymal tumor with EWSR1-rearrangement - a rare entity and source of potential diagnostic pitfalls	Tiago Maia
QP 16.6	P155. Electron microscopic observation of melanoma metastasis crossing the blood brain barrier	Rédouane Slimani
QP 16.7	P156. Expression of early B-cell Factor-1 in solitary fibrous tumor/hemangiopericytoma	Pietro Luigi Poliani
QP 16.8	P157. Elucidation of the transcriptomic consequences of KLF4 and TRAF7 mutations in secretory meningiomas	Signe Regner Michaelsen
QP 16.9	P159. A rare case of growth hormone secreting pituitary adenoma with ganglioglioma	Canan Tanik
QP 16.10	P160. Granular cell tumor of the neurohypophysis: report of two cases	Canan Tanik

## Thursday 3 June - Quick Pitch 17. Neuroinflammatory diseases

Chairs: Trevor Owens, Atul Anand

QP 17.1	P042. From a glial tumor to a tumefactive inflammatory demyelinating lesion – presentation during pregnancy	Joana Lopes
QP 17.2	P043. Neuroinflammation, epilepsy and psychological morbidity in patients undergoing surgery for intracranial meningioma	Jeppe Lohfert Haslund-Vinding
QP 17.3	P044. Exploring the neuroinflammatory response of the motor regions in human motor neurone disease	Bridget Ashford
QP 17.4	P045. Magnetic resonance imaging correlates of multiple sclerosis immunopathological patterns	Imke Metz
QP 17.5	P046. Bornavirus encephalitis in humans differs from what we know in animals	Yannik Vollmuth
QP 17.6	P047. IFN $\beta$ , not IFN $\alpha$ , induces a PD-L1hi FoxA1+ T regulatory signature	Louise Munk Rasmussen
QP 17.7	P048. The effect of siponimod on glial cell functions and viability in vitro	Julie Damgaard Christensen
QP 17.8	P049. Plasticity between FoxP3+Treg and FoxA1+Treg cells	Louise Munk Rasmussen
QP 17.9	P066. Immunotherapy induced hypophysitis: a case report	Elizabeth Byrne
QP 17.10	P067. Antibodies to MOG in CSF only: pathological findings support the diagnostic value	Sara Carta



# Quick Pitch Sessions

ECNP2021

## Thursday 3 June - Quick Pitch 18. Neurodegenerative diseases and leukoencephalopathies

Chairs: Gabor Kovacs, Vilde Pedersen

QP 18.1	P005. FTLD-UPS in CHMP2B-FTD	Ida Elisabeth Holm
QP 18.2	P006. Frontotemporal lobar degeneration: neuropathological classification of cases from the brain collection at Aarhus University Hospital, Denmark	Ida Elisabeth Holm
QP 18.3	P010. Frontotemporal lobar degeneration due to a novel GRN nonsense mutation with an associated 4-repeat tauopathy	Alberto Rábano Gutiérrez
QP 18.4	P029. Neuropathological investigation of lemur tyrosine kinase-2 (LMTK2) in Parkinson's disease dementia	János Bencze
QP 18.5	P030. Stimulation of subthalamic nucleus in Parkinson disease is associated with increased nerve fiber density in the internal globus pallidus	Margarida Calejo
QP 18.6	P034. Regulation of pathogenic gene expression through chromatin alterations in Parkinson's disease	Sergio Helgueta Romero
QP 18.7	P211. Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, phenotypic and clinical heterogeneity	María José López Martínez
QP 18.8	P223. Human post-mortem organotypic brain slices to study leukodystrophies	Bonnie Plug
QP 18.9	P227. The neurovascular unit in leukodystrophies: new insights from neuropathology	Parand Zarekiani
QP 18.10	P229. Diagnosis of FXTAS in the biopsy of a patient under study for leukoencephalopathy	Justino Jiménez Almonacid


# Supporters and Partner/Sister Organizations

ECNP2021


The organizers of the 12<sup>th</sup> European Congress of Neuropathology, the Scandinavian Neuropathological Society and the European Confederation of Neuropathological Society (Euro-CNS) are grateful for the support and participation of its supporters, exhibitors and Partner/Sister Organizations:



Neuropathology and Applied Neurobiology



# Exhibitors



ECNP2021

## Platinum

nanoString<sup>®</sup>

## Gold

**OLYMPUS**



## Silver



## Exhibitors



**VISIO**PHARM<sup>®</sup>



**CRC Press**  
Taylor & Francis Group



# Acknowledgements

ECNP2021

---

## The Congress Staff and Specialists

### **Euro-CNS office & ECNP program support**

**Ilja Huang**, Willemstad, Curaçao

### **ECNP2021 website and finance**

**Janne Christiansen**, Odense, Denmark

### **ePoster support and social media**

**Marjenka de Bell**, Rotterdam, the Netherlands

### **Registrations**

**Stefan de Bell**, Maastricht, the Netherlands

We are extremely grateful to our excellent staff for their meticulous work and flexibility, and to Tamsin Treasure-Jones of the **Learning Toolbox** for creating and supporting the ePoster platform;

to Dan Carroll and Dibyanarayan Hazra of **Firebird Conference Systems** for tailoring the registration and abstract system to our needs;

to Richard Belcher, Matt Walker, Igor Weileman and colleagues of **First Sight Media** and **Crowdcomms** for delivering and managing a completely novel and interactive platform for our congress;

to Monika and Frank Feistle of **Dustri-Verlag** for expertly copy-editing and producing the Abstract Book (Clinical Neuropathology) and to John Schmidt of **Genie Corp.** for elegantly designing and producing our program booklet.

Last but not least we are very indebted to Peder Andersen, Melena Schjøth and Helle Klestrup and Team at the **DIS Congress Service**, Lene Lysholt, Katrine Nielsen and Team at **Inspiring Denmark** and Team at **Odeon Congress Center** for carefully planning and preparing the meeting for the original congress dates in Odense.



# 12<sup>th</sup> European Congress of Neuropathology

**NOW VIRTUAL** • 31 May - 3 June 2021 